Navigation Links
UC Davis research shows that newly discovered drug reduces heart enlargement
Date:1/29/2009

DAVIS--Researchers at the University of California, Davis have discovered that a prototype drug reduces heart enlargement, one of the most common causes of heart failure.

Heart failure, which occurs when the heart can't pump enough blood throughout the body, affects 5 million people in the United States. The condition contributes to 300,000 deaths each year.

The research in the laboratories of cardiologist and cell biologist Nipavan Chiamvimonvat, Department of Cardiovascular Medicine, UC Davis School of Medicine, and entomologist Bruce Hammock, Department of Entomology, showed that the new class of drugs reduces heart swelling in rat models with heart failure.

"This holds promise to treat heart failure and other cardiovascular as well as kidney problems," said nephrology professor Robert Weiss, Department of Internal Medicine.

Similar compounds are now in clinical trials.

Ding Ai of Beijing, senior author of the paper published recently in the Proceedings of the National Academy of Sciences, worked as a Ph.D. student in the Chiamvimonvat and Hammock laboratories for a year.

"The study of rat models showed that heart failure is driven by high angiotensin associated with high blood pressure, artery disease and some kidney disease," Hammock said.

"When that occurs, a key enzyme called soluble epoxide hydrolase is increased."

The initial research on the enzyme sprang from studies on insect pest control in the Hammock lab.

"This enzyme," Chiamvimonvat said, "degrades anti-inflammatory and anti-hypertensive factors normally in the heart and blood, which may contribute to the pathological progression of heart failure."

Heart failure weakens the heart's pumping ability, she said. Blood and fluid can back up into the lungs; accumulate in the feet, ankles and legs (edema); and result in tiredness and shortness of breath. Coronary artery disease, high blood pressure and diabetes are the leading causes of heart failure.

The scientists showed they could inhibit the enzyme with a drug made by Paul Jones, a former postgraduate researcher at UC Davis. The swelling and ultimate failure of the heart is blocked and reversed, Hammock said.

"Interestingly, the increase in heart size associated with extreme exercise does not increase levels of the epoxide hydrolase, and exercise induced heart enlargement fortunately is not blocked by the drug."

This research follows earlier studies reported from the Chiamvimonvat laboratory on cardiac hypertrophy.

The two UC Davis laboratories collaborated with the laboratories of John Shyy at UC Riverside and Yi Zhu, Cardiovascular Sciences, Peking University Health Science Center. The 11-member research team also included Wei Pang, Nan Li, Ming Xu, Jun Yang and Youyi Zhang, all of China.

In a November 2006 paper in the Proceedings of the National Academy of Sciences, the Chiamvimonvat and Hammock laboratories showed that these enzyme inhibitors both block and reduce heart enlargement and irregular heart rhythms in a mouse model. The more recent work with the Zhu and Shyy laboratories extends these studies to show the involvement of angiotensin dependent enzyme induction in the process.

At the time, Chiamvimonvat said: "We need a better way to control and prevent enlargement of the heart to improve treatment options for patients and reduce mortality." "By blocking the pathway that leads to overgrowth of cardiac cells, we have shown that it is possible to prevent the progressive deterioration of heart function and the development of abnormal hearth rhythms."

The prototype drug published this week appears to be that "better way," the scientists said.


'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Related biology news :

1. UC Davis researchers find molecule that targets brain tumors
2. UC Davis discovery offers hope for treating kidney cancer
3. UC Davis team refines cancer treatments to reduce potential nerve damage
4. UC Davis researchers exploring gene therapy to fight AIDS
5. UC Davis researchers discover Achilles heel in pancreatic cancer
6. UC Davis researchers discover a key to aggressive breast cancer
7. UC Davis chemical ecologist wins major award
8. UC Davis researchers discover new drug target for inflammatory disease
9. UC Davis researchers define characteristics, treatment options for XXYY syndrome
10. UC Davis researcher leads climate-change discovery
11. UC Davis stem researchers demonstrate safety of gene therapy using adult stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis research shows that newly discovered drug reduces heart enlargement
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
(Date:4/28/2016)... , April 28, 2016 First quarter ... (139.9), up 966% compared with the first quarter of 2015 ... totaled SEK 589.1 M (loss: 18.8) and the operating margin was ... (loss: 0.32) Cash flow from operations was SEK 249.9 ... 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. The ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ON (PRWEB) , ... June 23, 2016 , ... STACS ... DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA as ... the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. “In ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
(Date:6/23/2016)... , June 23, 2016 ... market research report to its pharmaceuticals section with ... product details and much more. Complete ... across 151 pages, profiling 15 companies and supported ... at http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The ...
Breaking Biology Technology: